Your browser doesn't support javascript.
loading
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown, Landon C; Tucker, Matthew D; Sedhom, Ramy; Schwartz, Eric B; Zhu, Jason; Kao, Chester; Labriola, Matthew K; Gupta, Rajan T; Marin, Daniele; Wu, Yuan; Gupta, Santosh; Zhang, Tian; Harrison, Michael R; George, Daniel J; Alva, Ajjai; Antonarakis, Emmanuel S; Armstrong, Andrew J.
Afiliação
  • Brown LC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Tucker MD; Internal Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Sedhom R; Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Schwartz EB; Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Zhu J; Levine Cancer Institute, Charlotte, North Carolina, USA.
  • Kao C; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Labriola MK; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Gupta RT; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Marin D; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Wu Y; Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
  • Gupta S; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Zhang T; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Harrison MR; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • George DJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
  • Alva A; Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Antonarakis ES; Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA Andrew.armstrong@duke.edu.
J Immunother Cancer ; 9(3)2021 03.
Article em En | MEDLINE | ID: mdl-33653800
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Receptores de LDL / Biomarcadores Tumorais / Inibidores de Checkpoint Imunológico / Mutação / Neoplasias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Receptores de LDL / Biomarcadores Tumorais / Inibidores de Checkpoint Imunológico / Mutação / Neoplasias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos